bims-nakice Biomed News
on Natural killer cells
Issue of 2026–11–01
twelve papers selected by
Santosh Phuyal, Oslo Universitetssykehus



  1. J Clin Invest. 2026 Oct 27. pii: e204359. [Epub ahead of print]
      NK cell-based therapies for solid tumors are limited by poor persistence and progressive functional impairment. Here, we investigated how the strength of NKG2D stimulation shapes NK cell fate and therapeutic efficacy. Using B10G5, a MICA/B-targeting partial agonist antibody that attenuates NKG2D stimulation, we show that reduced NKG2D stimulation reshapes the intratumoral NK cell compartment by enriching EOMEShiTCF1hi stem-like NK (stemNK) cell pool, preserving functional diversity, and limiting mitochondrial oxidative stress and exhaustion induced by chronic sMIC/MIC exposure. Mechanistically, we identified the H3K27me3 demethylase KDM6B as a conserved regulator of NK cell stemness whose enzymatic activity is required to maintain the intratumoral stemNK cell pool. Conversely, strong NKG2D stimulation induced mitochondrial ROS accumulation and upregulated the inhibitory receptor LAG3 on NK cells. Attenuated NKG2D stimulation on human NK cells increased KDM6B expression and reduced repressive H3K27me3 mark at the TCF7 locus. Importantly, attenuated NKG2D stimulation during ex vivo expansion enhanced human NK cell in vivo persistence and antitumor efficacy following adoptive transfer. Together, these findings establish NKG2D stimulation strength as a key determinant of NK cell fate and function in solid tumors and identify a translatable concept to improve NK cell-based immunotherapy for solid tumors.
    Keywords:  Cancer immunotherapy; Immunology; NK cells; Oncology
    DOI:  https://doi.org/10.1172/JCI204359
  2. Cancer Immunol Immunother. 2026 Jul 28. pii: 257. [Epub ahead of print]75(11):
      Lung, colorectal, and liver cancers are among the most prevalent and lethal solid tumors globally. However, traditional therapeutic modalities and even current immunotherapeutic strategies such as chimeric antigen receptor (CAR)-T cell therapy have failed to deliver durable clinical benefits. This limitation is primarily attributed to the challenges posed by tumor heterogeneity, off-target toxicity, and, critically, to the inadequate assessment of the dynamic anti-tumor efficacy of these treatments. A major bottleneck in the preclinical evaluation of CAR-based immunotherapies for solid tumors is the overreliance on static endpoint cytotoxicity assays, including lactate dehydrogenase (LDH) release and chromium-51 (51Cr) release assays. These conventional methods merely quantify the final extent of tumor cell lysis and are unable to capture critical kinetic parameters-such as response latency, cytotoxicity rate, and the capacity for complete tumor elimination in vitro-all of which are pivotal for predicting clinical applicability. To address this gap, we employed real-time cell analysis (RTCA), a label-free and continuous monitoring technology, to systematically evaluate the anti-tumor potency of NKG2D CAR-engineered NK92 cells against lung (H1299), colorectal (HCT116), and liver (Hep3B) cancer cell lines. RTCA's unique capability to track tumor cell viability at 15-min intervals revealed that NKG2D CAR-engineered NK92 cells initiated cytotoxicity immediately without a lag phase, exhibited steeper cytotoxicity slopes, and achieved complete target cell eradication at an effector-to-target (E:T) ratio of 5:1-dynamic insights that remained undetectable with static assays. Notably, using this advanced cell killing detection method, we found that NKG2D CAR-engineered natural killer (NK) cells displayed cytotoxicity kinetics comparable to those of five times the number of unmodified NK cells against H1299, HCT116 and Hep3B cell lines. At E:T ratios of 5:1, the engineered cells also secreted significantly higher levels of pro-inflammatory cytokines (IFN-γ and TNF-α) compared to unmodified NK92 cells. This confirmed robust immune activation that coincided with real-time tumor killing. These findings not only demonstrate that NKG2D CAR-engineered NK92 cells represent a promising immunotherapeutic candidate for solid tumors, but also highlight RTCA as a useful and informative platform for monitoring cytotoxicity kinetics in real time and advancing the translational development of solid tumor immunotherapies.
    Keywords:  CAR-NK; Dynamic cytotoxicity analysis; NKG2D; Real-time cell analysis; Solid tumors
    DOI:  https://doi.org/10.1007/s00262-026-04510-z
  3. Front Immunol. 2026 ;17 1883517
       Introduction: Ovarian cancer ascites creates an immunosuppressive microenvironment that compromises NK cell function, yet the underlying mechanisms remain incompletely understood.
    Methods: We used ascites-conditioned NK cells and assessed their mechanophenotypes, including F-actin, cortical tension, and traction force, along with CDC42 activity. Transcriptomic analysis and bidirectional pharmacological manipulation of CDC42 were performed.
    Results: Ascites-conditioned NK cells exhibited a paradoxical cytoskeletal state-elevated F-actin yet reduced cortical tension and traction force-indicating a failure to translate actin polymerization into productive mechanical output. Mechanistically, ascites triggered de novo expression of the CDC42 negative regulators, CDC42EP1 and CDC42EP5, leading to suppressed CDC42 activity. Bidirectional pharmacological manipulation of CDC42 reciprocally regulated traction force and cytotoxicity, establishing a causal link between CDC42-dependent mechanics and NK cell killing. The near-perfect correlation between traction force and killing capacity positions traction force as a robust mechanobiomarker of NK cell competence.
    Discussion: These findings uncover a previously unrecognized role for CDC42 in governing NK cell mechanics and identify CDC42 as a therapeutically actionable node for restoring anti-tumor immunity in immunosuppressive microenvironments.
    Keywords:  CDC42; malignant ascites; mechanobiology; natural killer cells; ovarian cancer; traction force
    DOI:  https://doi.org/10.3389/fimmu.2026.1883517
  4. Curr Issues Mol Biol. 2026 Oct 04. pii: 1027. [Epub ahead of print]48(10):
      The Unfolded Protein Response (UPR) determines cell fate under endoplasmic reticulum (ER) stress, yet its temporal dynamics across different cell types and senescence states re-main poorly understood. In this study, we investigated UPR kinetics in endothelial and T-lymphoblastoid cell lines with distinct ER volumes, as well as in senescent FRSN cells undergoing ER expansion. Variations in ER volume were confirmed via confocal microscopy and flow cytometry. Using the 'gene response time' metric, we demonstrated experimentally and through mathematical modeling that the BiP response kinetics closely correlate with variations in ER volume. Applying this metric to presenescent FRSN cells with a significantly expanded ER, we found that their ER stress response machinery maintained a response time similar to that of exponentially growing FRSN cells, but exhibited a lower amplitude and a prolonged lag phase, leading to chronic ER stress signaling such as a protracted XBP1(S) expression profile. Scanning ion-conductance microscopy (SICM) revealed a significant decrease in the stiffness of the near-surface layer of presenescent cells, reflecting a rarefaction of the actin cortex and possibly cytoplasmic dilution. We propose that this structural remodeling could be associated with active intracellular transport impairment that weakens the temporal 'tethering' of the proteome to the genome upon cellular senescence. Consequently, the stress response machinery fails to scale proportionally with cell enlargement during senescence, creating a state of 'functional dilution'. This prevents enlarged senescent cells from mounting a scaled response, resulting in prolonged stress signaling and increased vulnerability to proteotoxic stress.
    Keywords:  cell geometry and volume; cellular senescence; endoplasmic reticulum (ER) stress; gene response time; mathematical modeling; scanning ion-conductance microscopy (SICM); temporal dynamics; unfolded protein response (UPR)
    DOI:  https://doi.org/10.3390/cimb48101027
  5. Methods Mol Biol. 2027 ;3089 251-264
      Subcellular architecture is tightly controlled and contributes to the maintenance of cell homeostasis. Organelles are regulated in size, shape, number, and position, all of which respond to changes in the extracellular environment. Lysosomes are of particular interest as they integrate various functions in the cells (nutrient sensing, metabolism, cell migration, and adhesion), serving as signaling hubs. Their function is tightly linked to their subcellular position, and deregulation of lysosome homeostasis leads to several diseases, including cancer. Therefore, methods allowing precise analysis of organelle subcellular distribution can aid in fundamental, diagnostic, and therapeutic approaches. Here, we provide a versatile image analysis pipeline using ImageJ and CellProfiler. This workflow allows for the quantification of subcellular lysosome distribution in living and fixed melanoma cells, and it is applicable to other subcellular compartments and to various cell types.
    Keywords:  CellProfiler; ImageJ; Immunofluorescence; Live-cell imaging; Lysosomes; Organelle positioning; Radial distribution; Subcellular architecture
    DOI:  https://doi.org/10.1007/978-1-0716-5619-8_17
  6. J Cell Biol. 2026 Dec 07. pii: e202609053. [Epub ahead of print]225(12):
      Export of secretory proteins at ER exit sites (ERES) has been described to occur via COPII-coated vesicles, tubules, or tunnels. These models have not been considered to reflect the flexibility of ERES but rather as mutually exclusive mechanisms. Here, we overview these export mechanisms, discuss why they coexist, and hypothesize about the biological relevance of carrier geometry. Finally, we suggest experimental avenues to resolve the disagreement.
    DOI:  https://doi.org/10.1083/jcb.202609053
  7. J Cancer Res Clin Oncol. 2026 Oct 23. pii: 202. [Epub ahead of print]152(10):
      Chimeric antigen receptor-natural killer (CAR-NK) cells combine innate cytotoxicity with antigen-directed killing and promise as an immunotherapy with lower cytokine toxicity than CAR-T approaches. However, clinical translation is limited by challenges in transduction, persistence, tumor infiltration, and the immunosuppressive tumor microenvironment (TME). We performed a comprehensive literature review of recent preclinical and early-phase clinical studies, engineering strategies (CAR design, transduction technologies, gene-editing), manufacturing and expansion protocols, and trial outcomes in this review. We noted a reference to the advantages of CAR-NK, like multimodal killing (CAR-dependent and innate pathways), potential for allogeneic "off-the-shelf" use, and favorable early safety profiles. However, NK-specific obstacles persist: lower viral transduction efficiencies, short in vivo persistence, poor infiltration into solid tumors, and TME-mediated suppression (TGF-β, adenosine, metabolic stress). Engineering countermeasures such as IL-15 expression, checkpoint receptor knockout, chemokine receptor co-expression (e.g., CXCR1/4), DAP10/DAP12-based signaling domains, and non-viral delivery (transposons/CRISPR) have shown preclinical promise. CAR-NK therapy has developed from concept to a clinically actionable treatment line for hematologic malignancies and shows emerging potential in solid tumors when combined with TME-modulating strategies. This review provides robust evidence about CAR-NK therapies in hematological and solid tumors, with a great emphasis on the challenges they encounter, strategies, and innovative approaches to overcome these challenges, and forward-looking perspectives to improve future therapeutic CAR-NK designs and clinical outcomes.
    Keywords:  CAR-NK; Cancer; Cellular therapy; Chimeric antigen receptor; Immunotherapy; Natural killer cells
    DOI:  https://doi.org/10.1007/s00432-026-06635-1
  8. Traffic. 2026 Dec;pii: e70057. [Epub ahead of print]27(4):
      At membrane contact sites (MCSs) between the endoplasmic reticulum (ER) and endolysosomal compartments, the Protrudin-PDZD8 complex promotes the maturation of endosomes into lysosomes, a process accompanied by acidification. Endosomal maturation is closely associated with both lysosomal acidification and calcium signaling; however, the molecular mechanisms linking the Protrudin-PDZD8 complex to these processes remain unclear. Here, we identified TMEM55B, a lysosome-localized protein, as a binding partner of the Protrudin-PDZD8 complex. TMEM55B has been reported to interact with the v-ATPase complex, suggesting a role in lysosomal function. Suppression of TMEM55B expression reduced the fluorescence of a lysosomal acidification probe, suggesting impaired lysosomal acidification. In addition, TMEM55B depletion attenuated lysosomal Ca2+ release and reuptake and reduced ATP-induced Ca2+ responses in the ER. These findings suggest impaired calcium-induced calcium release (CICR) at ER-lysosome MCSs. By contrast, mitochondrial Ca2+ dynamics were unaffected. Together, these results identify TMEM55B as a factor involved in maintaining lysosomal homeostasis and regulating calcium dynamics. Our findings suggest that TMEM55B cooperates with the Protrudin-PDZD8 complex to contribute to the regulation of lysosomal function at ER-lysosome MCSs.
    Keywords:  PDZD8; TMEM55B; calcium signaling; lysosome; membrane contact site
    DOI:  https://doi.org/10.1111/tra.70057
  9. Cell Rep. 2026 Oct 27. pii: S2211-1247(26)01304-5. [Epub ahead of print]45(11): 118225
      Glaucoma is a neurodegenerative disease that is in urgent need of neuroprotective therapies. We previously revealed the critical role of neuronal endoplasmic reticulum (ER) stress induced by optic nerve injury in glaucomatous neurodegeneration. We also demonstrated that modulation of the ATF4-CHOP branch of ER stress provides significant neuroprotection. Here, we present multiple new chemical series identified by high-throughput screening that inhibit ER stress-induced C/EBP homologous protein (CHOP) expression. We perform a structure-activity relationship analysis of one "hit" compound and establish two analogs with potent activities on inhibiting the expression of CHOP and activating transcription factor 4 (ATF4). We further demonstrate their neuroprotective efficacy in two optic neuropathy models; in both models, they increase survival of retinal ganglion cell somata and axons and preserve visual function. Together, this proof-of-concept evidence establishes the new ER stress modulators as promising candidates for further drug development to provide neuroprotective therapy for glaucoma and other optic neuropathies, and potentially for diverse CNS axonopathies.
    Keywords:  CHOP; CP: neuroscience; ER stress; glaucoma; neuroprotection; small molecules
    DOI:  https://doi.org/10.1016/j.celrep.2026.118225
  10. FEBS J. 2026 Oct 27.
      The traditional paradigm of intercellular communication is rapidly evolving. Tunneling nanotubes (TNTs) represent a distinct mode of intercellular communication, enabling the transfer of organelles, signaling molecules, and metabolic resources between spatially separated cells. Unlike soluble factor-mediated communication, TNTs establish direct physical connections that can support rapid and directional cargo transport, including mitochondrial transfer, with consequences for recipient-cell metabolism and function. In the immune system, TNT-mediated mitochondrial and other cargo transfer has been implicated in macrophage functional polarization, T-cell metabolic fitness, and natural killer (NK) cell-mediated immunity. In this review, we summarize the molecular characteristics of TNTs in immune cells, the regulation of their formation under inflammatory and metabolic stress, and the mechanisms and consequences of cargo transfer. We further examine the context-dependent nature of TNT-mediated communication, including its potential roles in host defense, tissue repair, tumor immune evasion, and pathogen dissemination. Finally, we critically evaluate transfer kinetics, quantitative scale, prevalence, in vivo evidence, and the technical limitations that currently constrain causal attribution and therapeutic translation.
    Keywords:  immune cells; metabolic communication; mitochondrial transfer; tunneling nanotubes
    DOI:  https://doi.org/10.1111/febs.70783
  11. Cell Stem Cell. 2026 Oct 28. pii: S1934-5909(26)00384-X. [Epub ahead of print]
      The rapid growth of new approach methodologies (NAMs), including organoids and organs-on-a-chip (OOCs), has revealed a need for interdisciplinary dialogue between cell biologists and bioengineers to develop human models that can best complement therapeutic development. Stem cell-derived and bioengineered human tissue models are redefining how we understand human physiology and pathophysiology, offering control that traditional preclinical models cannot provide. By recapitulating complex tissue microenvironments, multi-organ interactions, and patient-specific biology, these systems are bridging long-standing gaps in the drug development and clinical application pipelines. Here, we synthesize advances in organoids, OOCs, and other bioengineered technologies for translational medicine to identify remaining gaps, including challenges in reproducibility, validation, and regulatory acceptance. Emerging opportunities at the intersection of synthetic biology, multi-omics, machine learning, and genetic engineering are positioning NAMs not merely as improved experimental tools but as foundational platforms for accelerating therapeutic discovery and enabling personalized medicine at scale.
    Keywords:  NAMs; bioengineering; iPSCs; organ-on-chip; organoids; translation
    DOI:  https://doi.org/10.1016/j.stem.2026.10.003